




UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. APPLICATION NO.

09/831335



ACTION DUE *Reply To Missing Parts - 9/25/01*
Deadline To Reply - 2/25/02
DOCKETED BY *Jes 7/30/01*
ATTY *WCC*
FIRST NAMED APPLICANT *MALLETT*
ATTY. DOCKET NO. *ST 98096-US-*

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

INTERNATIONAL APPLICATION NO.

PCT/FR99/02752

I.A. FILING DATE

09 NOV 99

PRIORITY DATE

09 NOV 98

DATE MAILED: **25 JUL 2001**

AVENTIS PHARMACEUTICALS, INC.
 PATENTS DEPARTMENT
 ROUTE 202-206, P.O. BOX 6800
 BRIDGEWATER, NJ 08807 0800

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):

- | | |
|--|--|
| <input checked="" type="checkbox"/> U.S. Basic National Fee. | <input type="checkbox"/> Indication of Small Entity Status. |
| <input checked="" type="checkbox"/> Copy of the international application. | <input checked="" type="checkbox"/> Translation of the international application into English. |
| <input checked="" type="checkbox"/> Oath or Declaration of inventors(s). | <input type="checkbox"/> Translation of Article 19 amendments into English. |
| <input type="checkbox"/> Copy of Article 19 amendments. | <input checked="" type="checkbox"/> Other: IB 331, ISA/210-REFERENCES, DNA DISKETTE, SEQUENCE LISTING, STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES |
| <input checked="" type="checkbox"/> Priority Document. 2 | |
| <input checked="" type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any. | |
| <input checked="" type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English. | |

2. ☐ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.

- ☐ U.S. Basic National Fee. ☐ Copy of the international application.

3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
- ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
- ☐ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☒ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
- ☒ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

4. Additional claim fees of \$_____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5. ☐ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Enclosed: ☒ PCT/DO/EO/917

☐ PTO-875

☐ Notice of Defective Translation

☒ PCT/DO/EO/920

Christine S. Washington

FORM PCT/DO/EO/905 (March 2001)

Telephone: 703-305-3752

Recd

28 SEP 2001

28 SEP 2001

28 SEP 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Mallet et al.

Examiner: Unassigned

Art Unit: Unassigned

Serial No.: 09/831,335

Filed: May 8, 2001

Title: **NOVEL SYSTEM FOR REGULATING
TRANSGENE EXPRESSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EL 749687181 US in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

9/28/01
Date of Deposit

Signature *Skapadie*

**REPLY TO NOTIFICATION OF MISSING REQUIREMENTS
UNDER 35 U.S.C. 371**

Commissioner for Patents
Box PCT
Washington, D.C. 20231

Sir:

In response to the "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371" which was mailed on July 25, 2001 and which indicated that the oath or declaration and sequence listing were missing, Applicants submit herewith the Declaration, Sequence Listing paper copy and diskette, and a Statement regarding Content for the present application and a copy of Form PCT/DO/EO/917.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

William C. Coppola

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

10/03/2001 LLANDGRA 02330011 181982 09831335

02 FC:154

130.00 CH

Docket No. ST98036-US